Novel mechanism of antidepressant action: Norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism

International Journal of Neuropsychopharmacology

Volumn 10, Issue 5, 2007, Pages 575-578

  Stahl, Stephen M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AGOMELATINE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE; FLUOXETINE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MIRTAZAPINE; NORADRENALIN; NORADRENALIN TRANSPORTER; RITANSERIN; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

DOPAMINE RELEASE; DRUG MECHANISM; HUMAN; HYPNOSIS; INTERNEURON; MAJOR DEPRESSION; NORADRENALIN RELEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SEXUAL DYSFUNCTION; SLEEP; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; DOPAMINE; HEXAMETHONIUM; HUMANS; MELATONIN; MODELS, BIOLOGICAL; NOREPINEPHRINE;

EID: 34948817131     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145707008000     Document Type: Review

References (22)

1. Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Redman JR (1993). Successful use of S20098 and melatonin in an animal model of delayed sleep phase syndrome. Pharmacology Biochemistry and Behavior 46, 45-49.
2. Bourin M, Mocaer M, Porsolt R (2004). Antidepressant-like activity of S-20098 (agomelatine) in the forced swimming test in rodents : involvement of melatonin and serotonin receptors. Journal of Psychiatry & Neuroscience 29, 126-133.
3. Declerck A, Wauquier A, Van der Ham-Veltman P, Gelders Y (1987). Increase in slow-wave sleep in humans with the serotonin S2 antagonist ritanserin. The first exploratory polygraphic sleep study. Current Therapeutic Research, Clinical and Experimental 41, 427-432.
4. Dremencov E, Newman ME, Kinor N, Blatman-Jan G, Schindler CJ, Overstreet DH, Hadid G (2005). Hyperfunctionality of serotonin 2C receptor mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 28, 34-42.
5. Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T (2006). Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry 59, 1052-1060.
6. Filip M, Cunningham KA (2003). Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin 2C receptors in rat prefrontal cortex. Journal of Pharmacology and Experimental Therapeutics 306, 734-743.
7. Kennedy SH, Emsley R (2006). Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. European Neuropsychopharmacology 16, 93-100.
8. Lewy AJ, Lefler BJ, Emens JS, Bauer VK (2006). The circadian basis of winter depression. Proceedings of the National Academy of Sciences USA 103, 7414-7419.
9. Loo H, Hale A, D'haenen H (2002). Determination of the dose of agomelatine, a melatoninergic agonist and selective 5HT2C antagonist in the treatment of major depressive disorder : a placebo-controlled dose range study. International Clinical Psychopharmacology 17, 239-247.
10. Millan MJ (2005). Serotonin 5HT2C receptors as a target for the treatment of depressive and anxious states : focus on novel therapeutic strategies. Therapie 60, 441-460.
11. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D (2003). The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopamine and adrenergic pathways. Journal of Pharmacology and Experimental Therapeutics 306, 954-964.
12. Mouret J, Lemoine P, Minuit MP, Benkelfat C, Renardet M (1988). Effects of trazodone on the sleep of depressed subjects - a polygraphic study. Psychopharmacology (Berlin) 95 (Suppl.), S37-S43.
13. Ni YG, Miledi R (1997). Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proceedings of the National Academy of Sciences USA 94, 2036-2040.
14. Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, Carrasco JL, Stahl SM (2006). The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. Journal of Psychopharmacology. Published online : 18 October 2006. doi :10.1177/0269881106069938.
15. 2C antagonistic properties, in major depressive disorder. International Journal of Neuropsychopharmacology. Published online : 4 May 2007. doi:10.1017/S1461145707007766.
16. Porras G, DeMatteo V, Fracasso C, Lucas G, DeDeurwaerdere P, Caccia S, Esposito E, Spampinato U (2002). 5HT2A and 5HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26, 311-324.
17. Quera Salva M-A, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C, Lofaso F, Guilleminault C (2007). Major depressive disorder, sleep EEG and agomelatine: an open-label study. International Journal of Neuropsychopharmacology. Published online : 4 May 2007. doi:10.1017/ S1461145707007754.
18. Shayegan DK, Stahl SM (2004). Atypical antipsychotics : matching receptor profile to individual patient's clinical profile. CNS Spectrums 10 (Suppl. 11), 6-14.
19. Srinivasan V, Smits M, Spence W, Lowe AD, Kayumov L, Pani-Perumal SR, Parry B, Carinali DP (2006). Melatonin in mood disorders. World Journal of Biological Psychiatry 7, 138-151.
20. Stahl SM (1998). Not so selective serotonin reuptake inhibitors. Journal of Clinical Psychiatry 59, 343-344.
21. Stahl SM (2000). Essential Psychopharmacology (2nd edn). New York: Cambridge University Press.
22. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S (2004). A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Primary Care Companion. Journal of Clinical Psychiatry 6, 159-166.